PDF icon PDF herunterladen
Thromb Haemost 1978; 39(03): 675-682
DOI: 10.1055/s-0038-1646742
Original Article
Schattauer GmbH Stuttgart

Treatment of Congenital Factor VII Deficiency with a New Concentrate

G Mariani
1   The Department of Hematology, University of Rome, Italy
,
P M Mannucci
2   The Hemophilia & Thrombosis Centre Angelo Bianchi Bonomi University of Milan, Italy
,
M G Mazzucconi
1   The Department of Hematology, University of Rome, Italy
,
A Capitanio
2   The Hemophilia & Thrombosis Centre Angelo Bianchi Bonomi University of Milan, Italy
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 02. August 1977

Accepted 24. Dezember 1977

Publikationsdatum:
12. Juli 2018 (online)

 als PDF herunterladen  Lizenzen und Reprints
Preview

Summary

A new factor VII concentrate, made from ACD plasma by a process involving successive absorptions of cryoprecipitate supernatant on DEAE Sephadex and of the resulting supernatant on Al(OH)3, was administered to 10 patients with severe factor VII deficiency. 5 patients received only one dose for treatment of a single bleeding episode, the remaining 5 were given multiple infusions (47) for spontaneous hemorrhages or for the prevention of surgical bleeding. In vivo factor VII recovery ranged from 43 to 126% (average 88%) of the assayed in vitro activity of the concentrate. A dose of 0.5 u/kg was found to produce a 1% rise of the plasma factor VII levels. The mean half-life on injected factor VII as assessed in 7 kinetic studies was 205 min (range 168-234). Spontaneous bleeding was easily controlled by the concentrate and major surgical procedures (two tonsillectomies) could be performed without complications. 1 patient developed HBsAg positive hepatitis, but otherwise no serious side effects were observed. Factor VII concentrate reduces the risk of precipitating circulatory overload associated with the use of plasma and avoids the unnecessary rise of factor II, IX and X which follows prothrombin complex concentrates.